Trial · NCT01654536
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Number of Subjects Experiencing Nasal Mucosal Disorders, Septum Disorders, or Nasal Septum Perforations as Treatment Emergent Adverse Events (AEs; TEAE) | 0-6 months | |
| Primary | The Percentage of Subjects Experiencing Nasal Mucosal Disorders, Septum Disorders, or Nasal Septum Perforations as Treatment Emergent Adverse Events (AEs; TEAE) | 0-6 months | |
| Secondary | The Number of Subjects Experiencing Treatment Emergent Nasal AEs. | 0-6 months | |
| Secondary | The Percentage of Subjects Experiencing Treatment Emergent Nasal AEs. | 0-6 months | |
| Secondary | The Number of Subjects Experiencing Treatment Emergent AEs. | 0-6 months | |
| Secondary | The Percentage of Subjects Experiencing Treatment Emergent AEs. | 0-6 months | |
| Secondary | The Number of Subjects Experiencing Treatment Emergent Serious Adverse Events (SAEs). | 0-6 months | |
| Secondary | The Percentage of Subjects Experiencing Treatment Emergent Serious Adverse Events (SAEs). | 0-6 months | |
| Secondary | The Number of Subjects Experiencing Treatment Emergent AEs Causing Study Medication Discontinuation. | 0-6 months | |
| Secondary | The Percentage of Subjects Experiencing Treatment Emergent AEs Causing Study Medication Discontinuation. | 0-6 months | |
| Secondary | Number of Subjects With Development of or Worsening in Lens Opacities. | 0-6 months | |
| Secondary | Percentage of Subjects With Development of or Worsening in Lens Opacities. | 0-6 months | |
| Secondary | Number of Subjects With Increase ≥ 7 mm Hg From Baseline in Intraocular Pressure, or a Change to > 21 mm Hg, in Either Eye | 0-6 months | |
| Secondary | Percentage of Subjects With Increase ≥ 7 mm Hg From Baseline in Intraocular Pressure, or a Change to > 21 mm Hg, in Either Eye | 0-6 months | |
| Secondary | Number of Subjects With Change From Baseline in Best Corrected Visual Acuity. | 0-6 months | |
| Secondary | Percentage of Subjects With Change From Baseline in Best Corrected Visual Acuity. | 0-6 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01654536/registered